Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals

Backed by one-year EPS and revenue growth estimates of 21.72% and 16.23%, respectively, Eli Lilly and Company (NYSE:LLY) ...

Eli Lilly Expected to Post Higher 1Q Profit, Revenue on Continued Weight-Loss Drug Demand -- Earnings Preview

Eli Lilly is set to report first-quarter results before the market opens Thursday. Here is what you need to know. PROFIT: The pharmaceutical company is projected to post a profit of $6.61 billion, ...
BioSpace

Lilly can’t stop the dealing, with nearly $21B spent on M&A this year—so far

With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good ...
Hosted on MSN

Eli Lilly accelerates deal spree with $2.3B Ajax buyout

Eli Lilly announced a $2.3 billion acquisition of Ajax Therapeutics, marking its sixth deal of 2026, to expand its oncology capabilities with a next-generation JAK2 inhibitor for rare blood cancers.
Hosted on MSN

Eli Lilly to buy Ajax Therapeutics in $2.3B blood cancer deal

Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion, expanding its oncology portfolio with a next-generation JAK2 inhibitor for rare blood cancers. Ajax’s lead drug, AJ1-11095, ...
BioSpace

Q1 earnings take off, Lilly strikes many deals, Regeneron notches historic approval, FDA raises questions

Sanofi and Novartis kick off the heart of earnings season; Lilly strikes its fourth pact in as many weeks; Regeneron earns ...